IL308394A - The bispecific binding molecule - Google Patents

The bispecific binding molecule

Info

Publication number
IL308394A
IL308394A IL308394A IL30839423A IL308394A IL 308394 A IL308394 A IL 308394A IL 308394 A IL308394 A IL 308394A IL 30839423 A IL30839423 A IL 30839423A IL 308394 A IL308394 A IL 308394A
Authority
IL
Israel
Prior art keywords
binding molecule
bispecific binding
bispecific
molecule
binding
Prior art date
Application number
IL308394A
Other languages
English (en)
Hebrew (he)
Inventor
Ronny Falk
Per-Ola Freskg?Rd
Ken Honek
Lisa SANDERSJ??
Original Assignee
Bioarctic Ab
Ronny Falk
Freskg?Rd Per Ola
Ken Honek
Lisa SANDERSJ??
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab, Ronny Falk, Freskg?Rd Per Ola, Ken Honek, Lisa SANDERSJ?? filed Critical Bioarctic Ab
Publication of IL308394A publication Critical patent/IL308394A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL308394A 2021-06-11 2022-06-10 The bispecific binding molecule IL308394A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21179103 2021-06-11
PCT/EP2022/065915 WO2022258841A1 (fr) 2021-06-11 2022-06-10 Molécule de liaison bispécifique

Publications (1)

Publication Number Publication Date
IL308394A true IL308394A (en) 2024-01-01

Family

ID=76444245

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308394A IL308394A (en) 2021-06-11 2022-06-10 The bispecific binding molecule

Country Status (11)

Country Link
US (1) US20240141027A1 (fr)
EP (1) EP4351726A1 (fr)
JP (1) JP2024522627A (fr)
KR (1) KR20240019125A (fr)
CN (1) CN117693531A (fr)
AU (1) AU2022291255A1 (fr)
BR (1) BR112023025904A2 (fr)
CA (1) CA3220572A1 (fr)
IL (1) IL308394A (fr)
MX (1) MX2023014590A (fr)
WO (1) WO2022258841A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114499A1 (fr) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Ingénierie polypeptidique, bibliothèques et polypeptides ingéniérisés de liaison de chaîne lourde cd98 et de récepteur de transferrine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CN101421303B (zh) 2006-03-23 2013-06-12 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
PT2890712T (pt) 2012-08-29 2019-06-28 Hoffmann La Roche Transportador para a barreira hematoencefálica
MA45684A (fr) 2016-07-14 2019-05-22 Bioarctic Neuroscience Ab Protéine d'apport du cerveau

Also Published As

Publication number Publication date
CN117693531A (zh) 2024-03-12
MX2023014590A (es) 2023-12-15
CA3220572A1 (fr) 2022-12-15
BR112023025904A2 (pt) 2024-02-27
WO2022258841A1 (fr) 2022-12-15
EP4351726A1 (fr) 2024-04-17
KR20240019125A (ko) 2024-02-14
AU2022291255A1 (en) 2024-01-04
US20240141027A1 (en) 2024-05-02
JP2024522627A (ja) 2024-06-21

Similar Documents

Publication Publication Date Title
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
IL292698A (en) Amino-terminated scfv multispecific binding molecules
IL284926A (en) CD3-specific binding molecules
IL287555A (en) binding compounds
GB202116490D0 (en) Post-quantum certificate binding
IL286013A (en) cd3 binding molecules
EP4074923C0 (fr) Machine de liaison
IL308394A (en) The bispecific binding molecule
EP3945180C0 (fr) Machine de liaison
HUE065466T2 (hu) Kötözõgép
EP3941947A4 (fr) Molécules de liaison anti-her2
IL288561A (en) gal9-binding molecules with immunosuppressive activity
GB202010329D0 (en) Specific binding molecules
IL288562A (en) Activating gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202214753D0 (en) Bispecific binding agent
GB202205808D0 (en) Bispecific binding agent
GB202110360D0 (en) Binding molecules
GB202100737D0 (en) Binding molecules
GB202016611D0 (en) Binding molecules
GB202016386D0 (en) Binding molecules
GB202118101D0 (en) Bispecific binding agents
GB202315963D0 (en) Binding molecules
GB202314107D0 (en) Binding molecules
GB202312621D0 (en) Binding molecules